Valion Bio Inc (VBIO) AI Stock Analysis

Valion Bio, Inc. operates as a late-stage biopharmaceutical company based in San Antonio, Texas. Its lead drug candidate is Entolimod, a TLR5 agonist in late-stage development for the treatment of acute radiation syndrome. The pipeline also includes Entolimod for Neutropenia and lymphocyte exhaustion, as well as Entolasta, an immunologically optimized variant designed for chronic conditions such as immunosenescence. Additionally, the company provides CDMO services. Formerly named Tivic Health Systems, Inc., the company adopted the name Valion Bio, Inc. in April 2026.

Valion Bio generated $1.8M in revenue in FY2022 before revenue dropped 36.1% to $1.2M in FY2023 and fell 67.5% to $382,000 in FY2025. Between FY2019 and FY2025, revenue contracted at a compound annual growth rate of -1.9%. The gross margin stood at 8.4% in FY2025, compared to 24.4% in FY2023. Operating margin was -2067.5% in FY2025, with net income totaling -$8.9M. For the trailing twelve months ending June 30, 2026, revenue stood at -$86,000, with an operating margin of 19652.3% and EPS of -$177.91.

As of June 30, 2026, Valion Bio reported $2.1M in cash and short-term investments against total debt of $17.4M, resulting in net debt of $15.3M. Total assets were $32.5M and shareholders' equity was $11.9M. The current ratio stood at 1.11, while the debt-to-equity ratio was 1.46. In FY2025, the company used -$7.0M in operating cash flow and recorded free cash flow of -$7.0M, with capital expenditures of $38,000. The five-year share count change was 2271.9%.

With a market cap of $2.3M and an enterprise value of $17.8M, Valion Bio trades at a price-to-sales multiple of 1.5x and an EV to revenue multiple of 0.6x. This compares to a median price-to-sales multiple of 4.1x for the median of its US-listed Healthcare peers. Its price-to-book multiple is 0.5x. Over the past 12 months, the stock dropped 98.4% to close at $1.17 on October 16, 2026, underperforming the S&P 500 (SPY) return of 16.8%. The share price trades 93.0% below its 200-day average.

Valion Bio does not have published analyst recommendation counts or consensus price targets. Over the last 4 quarters, the company registered 3 EPS beats. The next scheduled earnings report date is November 13, 2026. For the trailing twelve months ending June 30, 2026, diluted EPS was -$177.91, following annual EPS figures of -$5469.38 in FY2023 and -$11193.04 in FY2022.

This page is an AI-written research summary of Valion Bio Inc (VBIO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VBIO income statement, VBIO balance sheet, VBIO key metrics, VBIO chart. See the VBIO stock overview for the latest quote and news.